Bisphosphonate use and breast cancer risk among women with ductal carcinoma in situ
Cancer Research — Li CL, Flanagan MR, Tang MTC, et al. | March 31, 2021
This study was sought to evaluate the relationship between bisphosphonate use and breast cancer risk among women with ductal carcinoma in situ. Researchers correlated 301 cases of women diagnosed with ductal carcinoma in situ (DCIS) and subsequent breast cancer and 587 individually matched controls (on age, DCIS diagnosis year, primary treatment, histology, grade, and disease-free survival time) who were diagnosed with DCIS but not a subsequent breast cancer utilizing a population-based nested case-control design. They identified information on recency and duration of bisphosphonate use from patient interviews and medical record reviews. A lower risk of developing an invasive breast cancer was seen in current users of bisphosphonates vs never users and users of bisphosphonates for greater than or equal to 48 months had a similar reduction in risk. This is the first study to report that bisphosphonate use is linked with a reduced risk of subsequent invasive breast cancer among women with a history of DCIS, which is consistent with the protective impact of bisphosphonates observed in other breast cancer settings. Bisphosphonates could effectively reduce risk along with the added advantages of its positive effects on bone health and fracture risk.
Read the full article on Cancer Research